Cystic Fibrosis Canada, Calgary and Southern Alberta Chapter is holding the 29th Annual 65 Roses Ladies Golf Classic event on June 25 to raise funds and awareness for cystic fibrosis (CF). The annual event will be presented by Lexus of Calgary and held at the…
Certain medications used to treat acid reflux are associated with an increased risk of hospitalization in cystic fibrosis (CF) patients, a study shows. Gastroesophageal reflux disease (GERD, aka acid reflux), which occurs when acid from the stomach rises into the esophagus causing heartburn, is more common in CF patients —…
It is now possible to identify genetic catalysts that accelerate the evolution of antibiotic resistance in bacteria, thanks to a team of researchers at University of Oxford, U.K. The findings could be used to design treatments to stop the development of antibiotic resistance. The data were published in the journal…
The new Cystic Fibrosis Innovation Hub at the University of Cambridge in the U.K. will encompass exciting new research about treatments and approaches for battling the disease, and take a “moon shot” at finding a cure. The hub is located at the University of Cambridge in the U.K. The Cystic Fibrosis…
A new population of lung stem cells capable of repairing the airways following a severe injury was identified in two preclinical studies. These cells’ ability to transform and replace several lung cell types may be explored for regenerative medicines to treat diseases such as cystic fibrosis.
The Therapeutics Development Network (TDN) of the Cystic Fibrosis Foundation has endorsed Proteostasis Therapeutics‘ trial assessing PTI-428 in combination with Symdeko (tezacaftor/ivacaftor) as a treatment for cystic fibrosis (CF). The Phase 2 trial will assess the safety, tolerability and pharmacokinetics of multiple doses of PTI-428 over a 28-day…
Enterprise Therapeutics recently closed a £29 million ($41 million) Series B financing round to help advance into clinical development the company’s pipeline of potential mucus-targeting therapies for cystic fibrosis (CF) and other lung diseases with a high unmet medical need. “We are very encouraged by progress the Enterprise team…
The U.S. Food and Drug Administration has given the go-ahead for MRT5005, Translate Bio’s lead candidate to treat the underlying cause of cystic fibrosis (CF), to be tested in a Phase 1/2 clinical trial. The company expects to begin dosing enrolled patients by mid-year. MRT5005 is designed to address…
Autogenic drainage physiotherapy can effectively improve the underlying lung mechanical impairment of cystic fibrosis (CF), a study shows. Respiratory physiotherapy is an important part of the treatment of patients with CF because it helps remove the mucus that accumulates in the lungs and that can ultimately lead to respiratory failure.
The two components of Orkambi act separately to trigger a liver enzyme that decreases the therapy’s ability to fight cystic fibrosis, a study reported. Vertex Pharmaceuticals created Orkambi by combining ivacaftor and lumacaftor (VX-809). It addresses the underlying cause of the disease — a gene mutation that leads to a build-up of…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.